IMNM

Immunome, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website immunome.com
Employees(FY) 37
ISIN US45257U1088

Performance

-16.07%

+16.83%

-28.25%

-17.39%

+2.52%

YTD

+32.97%

Profile

Immunome, Inc. operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Advanced Technical Analysis

Technical Analysis of IMNM 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 40 suggesting a neutral stance, and a Technical Score of 25 reinforcing the overall bearish outlook. This combination signals caution for potential investors as the market appears to be st...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of IMNM

Stock Rank

Recent News & Updates

2024-12-02 18:26
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-12-02 05:26
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-11-27 08:00
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference(Business Wire)
2024-11-27 00:22
Hedge Fund and Insider Trading News: Scott Bessent, Paloma Partners, Taula Capital Management, Immunome Inc (IMNM), AppLovin Corp (APP), and More(Insidermonkey)
2024-11-26 19:00
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference(Businesswire)
2024-11-26 06:23
Daily – Vickers Top Buyers & Sellers for 11/26/2024(Argus Research)
2024-11-25 09:05
Immunome Insider Bought Shares Worth $962,181, According to a Recent SEC Filing(MT Newswires)
2024-11-22 16:52
Immunome Files Prospectus for Stock Offering By Selling Shareholders(MT Newswires)
2024-11-15 06:28
Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags(Simply Wall St.)
2024-11-13 17:15
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates(Zacks)
2024-11-13 16:05
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update(Business Wire)
2024-11-13 03:05
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update(Businesswire)
2024-11-12 08:40
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates(Zacks)
2024-11-08 08:57
Stephens Starts Immunome With Overweight Rating, $30 Price Target(MT Newswires)
2024-11-05 08:00
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference(Business Wire)
2024-11-04 19:00
Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference(Businesswire)
2024-11-01 16:05
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-11-01 04:05
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-10-30 08:30
Immunome Advances with Strategic Asset Acquisition and Agreement(TipRanks)
2024-10-29 08:00
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021(Business Wire)
2024-10-28 20:00
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021(Businesswire)
2024-10-18 08:00
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium(Business Wire)
2024-10-17 20:00
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium(Businesswire)
2024-10-08 08:05
Immunome Appoints Roee Shahar as Executive Vice President, Commercial(Business Wire)
2024-10-08 08:00
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-10-07 20:05
Immunome Appoints Roee Shahar as Executive Vice President, Commercial(Businesswire)
2024-10-07 20:00
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-09-13 07:00
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024(Business Wire)
2024-09-12 19:00
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024(Businesswire)
2024-08-29 08:00
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference(Business Wire)

Page 1 of 8

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.